Probiotics: achieving a better regulatory fit.

IF 0.3 4区医学 Q4 FOOD SCIENCE & TECHNOLOGY

Food and drug law journal Pub Date : 2014-01-01

Diane E Hoffmann, Claire M Fraser, Francis Palumbo, Jacques Ravel, Virginia Rowthorn, Jack Schwartz

引用次数: 0

Abstract

The development and marketing of new probiotic products, substances containing live microorganisms that have a beneficial effect on the human body, have dramatically increased over the last few years. This article examines how the Food and Drug Administration and Federal Trade Commission currently regulate probiotics and makes recommendations as to changes that might be made to ensure that probiotic products are made available to the general public in a way that is both safe and effective.

本刊更多论文

益生菌:实现更好的调节契合。

新的益生菌产品，即含有对人体有益的活微生物的物质，其开发和销售在过去几年中急剧增加。本文研究了食品和药物管理局和联邦贸易委员会目前如何监管益生菌，并就可能做出的改变提出建议，以确保益生菌产品以安全有效的方式提供给公众。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Food and drug law journal 医学-食品科技

CiteScore

0.20

自引率

50.00%

发文量

审稿时长

>36 weeks

期刊介绍： The Food and Drug Law Journal is a peer-reviewed quarterly devoted to the analysis of legislation, regulations, court decisions, and public policies affecting industries regulated by the U.S. Food and Drug Administration (FDA) and related agencies and authorities, including the development, manufacture, marketing, and use of drugs, medical devices, biologics, food, dietary supplements, cosmetics, veterinary, tobacco, and cannabis-derived products. Building on more than 70 years of scholarly discourse, since 2015, the Journal is published in partnership with the Georgetown University Law Center and the O’Neill Institute for National & Global Health Law. All members can access the Journal online. Each member organization and most individual memberships (except for government, student, and Emeritus members) receive one subscription to the print Journal.